referring to express
Dementia breakthrough: Results from sea monster game will help diagnose disease
Dementia breakthrough: Results from sea monster game will help diagnose disease
The game, Deutsche Telekom's Sea Hero Quest, was specifically designed to create the world's largest sourced data set to improve the understanding of spatial navigation, in a bid to manage the growing threat dementia.Results from the study have revealed spatial navigation abilities decline from early adulthood and found there are fundamental differences in navigation strategies applied by men and women.More than 2.4 million people have now taken part in the study since it launched in May 2016, generating over 63 years of gameplay – which equates to over 9,400 years' worth of equivalent lab-based research in this area.The second largest study of this kind contained just 599 participants.
as well fox2detroit
Mother of boy battling brittle bone disease looks for help - Story
Mother of boy battling brittle bone disease looks for help - Story
Defying doctors, boy with rare bone disease celebrates 8th birthday Local News Mother of boy battling brittle bone disease looks for help "Doctors told me Amere wasn't going to make it past 4 years old."- "Doctors told me Amere wasn't going to make it past 4 years old."But on Tuesday, Grenisha King was able to celebrate her son's 8th birthday with cake and balloons.Amere smiled in school as his classmates sang to him.
in the same way fiercebiotech
Rare disease biotech Glycomine raises $12M, with help from Chiesi venture arm
Rare disease biotech Glycomine raises $12M, with help from Chiesi venture arm
In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from Sanderling Ventures and Chiesi Ventures.The round also saw money injected from "existing high net worth individuals," as well as patients.Glycomine said in a statement that it will use the cash to finish off IND-enabling preclinical tests and kick-start clinical studies of its substrate replacement therapy in patients with congenital disorder of glycosylation type Ia (CDG-Ia), as well as to speed up discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1).This disease, an inherited metabolic disorder, is terminal in around 20% of young children, with death usually coming due to infection, liver problems, or heart disease.
No comments:
Post a Comment